ClinicalTrials.Veeva

Menu
M

Medical Research Group of Central Florida | Orange City, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rapastinel
Viloxazine
SPN-812
Troriluzole
Cariprazine
SPD489
SHP465
Ziprasidone
Bryostatin
Aticaprant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 63 total trials

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Active, not recruiting
Depressive Disorder, Major
Drug: Aticaprant

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[...

Enrolling
Tourette Syndrome
Drug: Ecopipam

The primary purpose of this trial is to evaluate the safety and tolerability of centanafadine QD XR in pediatric subjects with ADHD.

Active, not recruiting
Attention Deficit/Hyperactivity Disorder
Drug: Centanafadine Hydrochloride

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling
Attention-Deficit/Hyperactivity Disorder
Drug: Placebo
Drug: 100mg SPN-812

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive d...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

Trial sponsors

AbbVie logo
Pfizer logo
Shire logo
Allergan logo
Roche logo
Sumitomo Pharma logo
Biohaven logo
Janssen (J&J Innovative Medicine) logo
Supernus Pharmaceuticals logo
Viatris logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems